


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on June 30, 2009.



Frank C. Eisenschenk, Ph.D., Patent Attorney

STATEMENT OF SUBSTANCE OF  
INTERVIEW

Examining Group 1633

Patent Application

Docket No. ARS.126

Serial No. 10/573,369

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Maria B. Marvich, Ph.D.  
Art Unit : 1633  
Applicants : Philippe Dupraz, Michel Kobr  
Serial No. : 10/573,369  
Filed : December 26, 2006  
Confirm. No. : 2134  
For : Leader Sequences for Use in Production of Proteins

MS ISSUE FEE

Commissioner for Patents


P.O. Box 1450

Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 C.F.R. §1.133

The applicants wish to thank Examiner Marvich for the courtesy of the telephonic examiner interview conducted on June 11, 2009 with the undersigned. The remarks set forth in the Interview Summary Form are consistent with the substance of that interview and are believed to address the outstanding issues as discussed during the interview. The interview clarified that Group IV of the restriction requirement should encompass claims 37-40 in part, drawn to a method of producing a polypeptide of interest using a vector comprising a sequence encoding tPA.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik

P.O. Box 142950

Gainesville, FL 32614-2950

FCE/jb